EnGeneIC

EnGeneIC is a clinical-stage biopharmaceutical company based in Lane Cove West, Sydney, Australia, with additional operations in New York, USA.

Founded in 2001 by Dr. Jennifer MacDiarmid and Himanshu Brahmbhatt, the company focuses on developing targeted anti-cancer and anti-infective therapies using its proprietary EnGeneIC Dream Vector (EDVTM) nanocell platform. This innovative platform utilizes non-living nano-cells to directly target tumor cells while harnessing the patient’s immune system, aiming to minimize systemic toxicity and enhance anti-tumor responses. The EDVTM platform serves as a versatile delivery vehicle for chemotherapeutics, functional nucleic acids, and vaccines, including a COVID-19 EDV vaccine. EnGeneIC is currently conducting Phase 2a clinical trials for various oncology indications, including pancreatic cancer and mesothelioma, across Australia, Singapore, and the US. The company engages in research, development, and manufacturing of its targeted therapies and operates primarily in the B2B space, collaborating with healthcare providers, research institutions, and pharmaceutical companies to advance cancer treatment options.